Genetic and Environmental interactions in COPD, Cystic Fibrosis and Other (rare) respiratory pathologies - Team GEIC2O


Head Sophie Lanone

Tél.: +33-(0)1 49 81 37 25


Latest news from the team


March 20, 2024


The PolluRisk platform honored by the Ile-de-France Region as part of the 30th anniversary of the SESAME system. The main objective of the SESAME system is to make the Ile-de-France region a world reference in science and technology by giving laboratories the necessary means to develop new projects and to implement original experimental research systems. More informations


March 14, 2024


Congratulations to Khadeeja Adam SY, GEIC2O team, winner of the prize for best active participation at the 17th European CF Young investigators’ Meeting! Learn more



February 12, 2024


Congratulations to Benjamin Simonneau from Pascal Fanen’s group, in the GEIC20 team, who was awarded the prize for best poster at the Colloque Jeunes Chercheurs organised by the patient association Vaincre la Mucoviscidose on Tuesday 6 February 2024! To find out more

January 25, 2024


Corrective role of resolvin E1 in ciliary dyskinesia in cystic fibrosis, a study published in PNAS by Valérie URBACH’s groupSophie LANONE’s teamMore info



May 9, 2023


Congratulations to Sophie Lanone of IMRB’s GEIC2O team and Patrice Coll of LISA-UPEC/UPCité/CNRS, for their article “Air pollution, so complex to reproduce in the laboratory” in the Figaro Santé on Monday May 8! Read more on Le Figaro Santé, Monday, May 8, 2023



Research theme:


The general scientific objective of GEIC2O team is to understand the interplay between genetic and environmental factors in the development of lung diseases throughout the life (namely from children to adults).


We particularly focus on lung diseases of non-genetic (Chronic Obstructive Pulmonary Disease or COPD) and genetic (Cystic Fibrosis and surfactant disorders) origins.


The large pluridisciplinarity of GEIC2O team staff comprising MD (lung specialists – adult and pediatricians, occupational medicine, geneticists, ear/nose/throat specialists, and lung pathologist) as well as PhD (in cellular and molecular biology, biochemistry, genetic, bioinformatics and respiratory physiology) allows us to develop a comprehensive scientific approach ranging from in vitro experimental work to preclinical models and patient cohorts.





Four main research axes:

 Molecular bases of cigarette smoke-induced COPD

 Genetic and cellular bases of CF and surfactant disorders

 Resolution of inflammation in lung diseases – New theme

 Environmental aggressions and course of lung diseases




EU (COST actions, H2020 REMEDIA –, ANR, Programme d’investissement d’avenir (LabEx SERENADE, EquipEx NanoID –, ANSES, Chancellerie des Universités, Vaincre la Mucoviscidose, Centre de compétence en Nanosciences d’île de France (C’Nano), Société de pneumologie de langue française (SPLF), Île de France Region (DIM QI2 –, SESAME, …), …




Main results:


  • – Role of new molecular mechanism (PGE2, p53, mesenchymal stem cell features of lung fibroblasts) in COPD pathophysiology (Thorax 2018, Cell Death Dis 2018, JACI 2017, AJRCMB 2016, Arch Toxicol 2015, AJRCCM 2013)
  • – Implementation of a new strategy, which combines in silico and in vitro analyses to anticipate the occurrence of “splicing-causing” mutations in CFTR exons (Human Mutat 2014, 2013)
  • – First description of the molecular mechanism of an exonic SFTPC mutation, which unmasked a splicing defect (Eur J Human Genet 2017)
  • – Expansion of the phenotypic spectrum of interstitial lung disease i.e. due to NKX2-1 or ABCA3 mutations (Respir Med 2017, ERJ 2014)
  • – Step towards personalized therapy of CF, with the identification of new therapeutic targets (Br J Pharmacol 2016, Hum Mutat 2013, Int J Biochem Cell Biol 2013)
  • – Identification of the relations between asbestos exposure, pleural plaques, and occurrence of mesothelioma, lung cancer or colon cancer in asbestos-exposed patients (EHP 2017, ERJ 2014, AJRCCM 2014, J Natl Cancer Inst 2014)
  • – First evidence of respiratory consequences of occupational exposure to metal NP in welders ( Rep. 2018, Nanotoxicology 2016, Particle & Fibre Toxicol 2014)
  • – Long-term effects of maternal exposure to environmental contaminants (cigarette smoke, metal nanoparticles) during gestation; susceptibility factors to develop lung diseases in adulthood (Environment Health Perspect 2017, Nanotoxicology 2017)?
  • – NP physico-chemical characteristics such as diameter, length, surface properties or chemical nature are critical determinants of their effects on lung inflammation, oxidative stress and autophagy, as well as their intracellular modification (Autophagy 2018, Particle & Fibre Toxicol 2016, 2013, 2011, 2010, AJRCMB 2013)


Organizational chart of GEIC2O:

Organigramme GEIC2O – October 2023



Selected publications

Cohignac V, Landry M, Ridoux A, Pinault M, Annangi B, Gerdil A, Herlin-Boime N, Mayne-L 'hermite M, Haruta M, Codogno P, Boczkowski J, Pairon JC, Lanone S. Carbon nanotubes but not spherical nanoparticles block autophagy process by a shape-related targeting of lysosomes in murine macrophages.

Autophagy. 2018;14(8):1323-1334. doi: 10.1080/15548627.2018.1474993. Epub 2018 Jul 30.

Even B, Fayad-Kobeissi S, Gagliolo JM, Motterlini R, Boczkowski J, Foresti R, Dagouassat M. Heme oxygenase-1 induction attenuates senescence in chronic obstructive pulmonary disease lung fibroblasts by protecting against mitochondria dysfunction.

Aging Cell 2018; Volume 17, Issue 6, December 2018, e12837

Drummond D, Baravalle-Einaudi M, Lezmi G, Vibhushan S, Franco-Montoya ML, Hadchouel A, Boczkowski J, Delacourt C. Combined Effects of in Utero and Adolescent Tobacco Smoke Exposure on Lung Function in C57Bl/6J Mice.

Environ Health Perspect. 2017;125(3):392-399.

Nattes E, Lejeune S, Carsin A, Borie R, Gibertini I, Balinotti J, Nathan N, Marchand-Adam S, Thumerelle C, Fauroux B, Bosdure E, Houdouin V, Delestrain C, Louha M, Couderc R, De Becdelievre A, Fanen P, Funalot B, Crestani B, Deschildre A, Dubus JC, Epaud R. Heterogeneity of lung disease associated with NK2 homeobox 1 mutations.

Respir Med. 2017 Aug;129:16-23.

Delestrain C, Simon S, Aissat A, Medina R, Decrouy X, Nattes E, Tarze A, Costes B, Fanen P, Epaud R. Deciphering the mechanism of Q145H SFTPC mutation unmasks a splicing defect and explains the severity of the phenotype.

Eur J Hum Genet. 2017 Jun;25(6):779-782.

Paris C, Thaon I, Hérin F, Clin B, Lacourt A, Luc A, Coureau G, Brochard P, Chamming's S, Gislard A, Galan P, Hercberg S, Wild P, Pairon JC, Andujar P. Occupational asbestos exposure and incidence of colon and rectal cancers in French men: The Asbestos-Related Diseases Cohort (ARDCo-Nut).

Environ Health Perspect. 2017;125: 409-415.

Landry M, Pinault M, Tchankouo S, Charon É, Ridoux A, Boczkowski J, Mayne-L'Hermite M, Lanone S. Early signs of multi-walled carbon nanotbues degradation in macrophages, via an intracellular pH-dependent biological mechanism; importance of length and functionalization

Part Fibre Toxicol. 2016 Nov 24;13(1):61

Rocca J, Manin S, Hulin A, Aissat A, Verbecq-Morlot W, Prulière-Escabasse V, Wohlhuter-Haddad A, Epaud R, Fanen P, Tarze A. New use for an old drug: COX-independent anti-inflammatory effects of sulindac in models of cystic fibrosis.

Br J Pharmacol. 2016 Jun;173(11):1728-41.

Andujar P, Simon-Deckers A, Galateau-Sallé F, Fayard B, Beaune G, Clin B, Billon-Galland MA, Durupthy O, Pairon JC, Doucet J, Boczkowski J, Lanone S. Role of metal oxide nanoparticles in histopathological changes observed in the lung of welders.

Part Fibre Toxicol. 2014;11:23.

Epaud R, Delestrain C, Louha M, Simon S, Fanen P, Tazi A. Combined pulmonary fibrosis and emphysema syndrome associated with ABCA3 mutations.

Eur Respir J. 2014 Feb;43(2):638-41.

Pairon JC, Andujar P, Rinaldo M, Ameille J, Brochard P, Chamming’s S, Clin B, Ferretti G, Gislard A, Laurent F, Luc A, Wild P, Paris C. Asbestos exposure, pleural plaques and the risk of death from lung cancer.

Am J Respir Crit Care Med. 2014;190:1413-20.

Pairon JC, Laurent F, Rinaldo M, Clin B, Andujar P, Ameille J, Brochard P, Chamming’s S, Ferretti G, Galateau-Sallé F, Gislard A, Letourneux M, Luc A, Schorlé E, Paris C. Pleural plaques and the risk of pleural mesothelioma.

J Natl Cancer Inst. 2013;105: 293-301.

Dagouassat M, Gagliolo JM, Chrusciel S, Bourin MC, Duprez C, Caramelle P, Boyer L, Hue S, Stern JB, Validire P, Longrois D, Norel X, Dubois-Randé JL, Le Gouvello S, Adnot S, Boczkowski J. The cyclooxygenase-2-prostaglandin E2 pathway maintains senescence of chronic obstructive pulmonary disease fibroblasts.

Am J Respir Crit Care Med. 2013;187(7):703-14.

Aissat A, de Becdelièvre A, Golmard L, Vasseur C, Costa C, Chaoui A, Martin N, Costes B, Goossens M, Girodon E, Fanen P, Hinzpeter A. Combined Computational-Experimental Analyses of CFTR Exon Strength Uncover Predictability of Exon-Skipping Level.

Hum Mutat. 2013 Jun;34(6):873-81.

Hinzpeter A, Aissat A, de Becdelièvre A, Bieth E, Sondo E, Martin N, Costes B, Costa C, Goossens M, Galietta LJ, Girodon E, Fanen P. Alternative splicing of in-frame exon associated with premature termination codons: implications for readthrough therapies.

Hum Mutat. 2013 Feb;34(2):287-91.